neisseria lactamica expressing neisserial adhesin A

Neisseria lactamica expressing neisserial adhesin A is a genetically modified live biotherapeutic and vaccine candidate designed to prevent meningococcal disease. The platform utilizes *Neisseria lactamica*, a non-pathogenic commensal bacterium that naturally colonizes the human nasopharynx and has been shown to competitively exclude *Neisseria meningitidis*. This specific strain is engineered to stably express the Neisserial adhesin A (NadA) protein, a surface adhesin and a key component of existing protein-based meningococcal vaccines (such as 4CMenB). When administered intranasally, the bacteria colonize the upper respiratory tract, providing a physical and biological barrier against pathogen colonization while simultaneously acting as a mucosal delivery system that induces robust, cross-reactive systemic and mucosal immune responses against NadA-expressing meningococcal strains. Developed primarily by researchers at the University of Southampton, this approach represents a novel method of "bacterial interference" combined with live-vector immunization.

Other names

Genetically modified Neisseria lactamica expressing NadANadA-expressing Neisseria lactamicaGM Neisseria lactamica